Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 02/20 03:49:03 pm
36.47 USD   +0.58%
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19Stocks mostly up
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) - Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 07:16pm CET

TIME: 8 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) holds a meeting of the Arthritis Advisory Committee to discuss supplemental new drug applications 203214 supplement 17, for XELJANZ (tofacitinib) tablets and 208246 supplement 3, for XELJANZ XR (tofacitinib) extended release tablets submitted by Pfizer Inc., for the treatment of adult patients with active psoriatic arthritis.

DATE: August 3, 2017

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.

CONTACT: Philip Bautista, 301-796-9001, [email protected]

(c) 2006 Federal Information & News Dispatch, Inc., source Washington Daybook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
02/19UK shares retreat as Reckitt disappoint
RE
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19Stocks mostly up
AQ
02/17PFIZER : Avelumab Falls Short in Phase III NSCLC Trial
AQ
02/17Merck/Pfizers cancer immunotherapy latecomer hits a snag
AQ
02/16DOW MOVERS : Mcd, csco
AQ
02/16PFIZER : Receives Breakthrough Therapy Designation from FDA for PF-04965842 an o..
AQ
02/16PFIZER : FDA investigating misuse, abuse of gabapentinoids
AQ
02/16PFIZER : Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of ..
AQ
02/16PFIZER : T Mobile Us (TMUS) Holder Swarthmore Group Increased Its Stake by $311,..
AQ
More news
News from SeekingAlpha
02/173 THINGS IN BIOTECH YOU SHOULD LEARN : February 17, 2018 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16BRUTE FORCE : Bring On The Machines 
02/16Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q4 2017 Update 
02/133 THINGS IN BIOTECH YOU SHOULD LEARN : February 12, 2018 
Financials ($)
Sales 2018 54 410 M
EBIT 2018 20 806 M
Net income 2018 13 101 M
Debt 2018 22 213 M
Yield 2018 3,79%
P/E ratio 2018 16,53
P/E ratio 2019 15,38
EV / Sales 2018 4,38x
EV / Sales 2019 4,24x
Capitalization 216 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 40,3 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.84%216 135
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359
AMGEN3.23%133 241